This portal is your one-stop-shop for all your needs and questions concerning BMS products in Switzerland! These are some examples of the things you can find:
Ready to explore? Please use your existing DocCheck Login to access one of our therapeutic area portals or to access the comprehensive BMS Medicines or News & Events overview
November 2023 – Q4W 480 mg dosing with Nivolumab is approved in all melanoma indications.
Q4W dosing is approved for all Nivolumab monotherapy as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment in melanoma.
September 2023 – Swissmedic approved lisocabtagene maraleucel (BREYANZI®) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
July 2023 – Nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumour size ≥ 4 cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumour expression ≥ 1 % in adults